Search results
Key Reasons to Retain Danaher (DHR) Stock in Your Portfolio
Zacks via Yahoo Finance· 2 years agoDanaher Corporation DHR is backed by multiple tailwinds despite some margin pressure due to raw...
The Zacks Analyst Blog Highlights Walmart, Chevron, Danaher, Intel and Lowe's
Zacks via Yahoo Finance· 1 year agoFor Immediate Release Chicago, IL – April 25, 2023 – Zacks.com announces the list of stocks featured...
Danaher (DHR) Provides Improved Q4 Core Revenue Growth Guidance
Zacks via Yahoo Finance· 1 year agoBenefiting from strong growth in Cepheid's molecular diagnostics among other factors, Danaher (DHR)...
Here's Why You Should Hold on to Danaher (DHR) Stock Now
Zacks via Yahoo Finance· 1 year agoThe DBS initiatives, cost management actions and steady demand across major end markets augur well...
Stock Market Sell-Off: Is Danaher Stock a Buy?
Motley Fool· 2 years agoA glance at Wall Street analysts' expectations for Danaher's growth for 2022 and 2023 hardly suggests it's a growth stock. After all, revenue growth of...
Here's Why Hold Strategy is Apt for Danaher (DHR) Stock Now
Zacks via Yahoo Finance· 1 year agoStrength across the Life Sciences segment, inorganic activities and DBS initiatives bode well for...
Top Stock Reports for Berkshire Hathaway, Roche & Thermo Fisher Scientific
Zacks via Yahoo Finance· 1 year agoToday's Research Daily features new research reports on 16 major stocks, including Berkshire...
Don’t be duped by doomsayers, billionaire Ken Fisher says — this mega-cap-led surge has legs. Here...
TipRanks via Yahoo Finance· 11 months agoIt hasn’t gone unnoticed that the market’s strong performance this year has been led by the...
Life Science Giant Danaher Warns Of Sales Decline In 2024; Says 'Pandemic Has Transitioned To An...
Benzinga via Yahoo Finance· 4 months agoTuesday, Danaher Corp (NYSE:DHR) reported a fourth-quarter 2023 adjusted EPS of $2.09, down from...
Danaher (DHR) Gears Up to Post Q4 Earnings: Is a Beat in Store?
Zacks via Yahoo Finance· 4 months agoDanaher's (DHR) Q4 earnings are likely to have been hurt by weakness in the Biotechnology and...